Cold-induced metabolic flexibility explains ethnic disparities among individuals with obesity and insulin resistance
April 6, 2026 / Cold-Induced Thermogenesis / Metabolic Flexibility / Insulin Resistance / Ethnic Differences Metabolism / Brown Adipose Tissue
Cold-induced thermogenesis reveals ethnic differences in metabolic flexibility; Chinese individuals show stronger associations between energy utilization shifts and improved insulin sensitivity, while Asian Indians exhibit blunted responses, highlighting the need for ethnicity-specific metabolic interventions in obesity and insulin resistance.
Scientists Uncover New Metabolic Effects Beyond Weight Loss of Mounjaro
April 6, 2026 / Tirzepatide Mechanism / Brown Adipose Tissue / Energy Expenditure / GLP1 GIP Therapy / Obesity Metabolism
Tirzepatide enhances metabolic health beyond appetite suppression by activating brown adipose tissue, increasing energy expenditure and improving glucose and lipid metabolism, suggesting a dual mechanism for obesity and diabetes treatment.
Switch to DOR-Based ART Does Not Improve Weight Outcomes in HIV and Obesity
April 3, 2026 / HIV Obesity Management / Antiretroviral Therapy Switch / Doravirine ART / INSTI Weight Gain / Metabolic Outcomes HIV
Switching from INSTI- to doravirine-based ART in obese patients with HIV did not yield clinically meaningful weight loss or metabolic improvements, indicating that ART modification alone is insufficient for managing obesity-related metabolic risk.
New obesity definition could delay treatment and widen health gaps
April 7, 2026 / Obesity Classification / BMI Limitations / Cardiometabolic Risk / Clinical Obesity Definition / Health Disparities
A new obesity classification incorporating organ dysfunction and anthropometrics may improve precision but risks delayed treatment and underdiagnosis, potentially widening health disparities compared to traditional BMI-based definitions.
Natural compound nigericin reduces endotrophin tied to obesity, study shows
April 1, 2026 / Nigericin Mechanism / Endotrophin Inhibition / Obesity Inflammation / Insulin Sensitivity / Metabolic Disease Therapy
Nigericin inhibits endotrophin production in adipose tissue, reducing inflammation, fibrosis, and improving insulin sensitivity in obesity models, highlighting a novel targeted mechanism for treating metabolic diseases like type 2 diabetes.
Aelis Farma Awarded a €458k Grant Under France 2030 in Nouvelle-Aquitaine to Support Development of Its Program in Obesity and Associated Metabolic Diseases
April 6, 2026 / CB1 Receptor Therapy / Obesity Drug Development / Metabolic Disease Treatment / France 2030 Funding / Biotech R&D
Aelis Farma secured €458k to advance CB1 receptor-targeting therapies for obesity and metabolic diseases, supporting preclinical development of novel signaling inhibitors addressing metabolic dysfunction and related peripheral disorders.
FDA approves Lilly obesity pill, triggering battle with Novo Nordisk
April 1, 2026 / Orforglipron Approval / GLP1 Oral Therapy / Obesity Treatment Drugs / Semaglutide Competition / Weight Loss Pharmacotherapy
FDA approval of oral GLP-1 agonist orforglipron expands obesity treatment options, demonstrating significant weight loss and intensifying competition with semaglutide, highlighting a shift toward convenient, scalable metabolic therapies.
Unlike GLP-1s, This Hormone Targets Metabolism Instead of Appetite
April 2, 2026 / FGF21 Hormone / Metabolic Rate Regulation / Hindbrain Signaling / Obesity Treatment Pathways / MASH Therapeutics
FGF21 promotes weight loss by increasing metabolic rate via hindbrain signaling, distinct from GLP-1 appetite suppression, offering a novel therapeutic pathway for obesity and MASH with potential for more targeted metabolic interventions.
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association’s 2026 Scientific Sessions
April 2, 2026 / CBL514 Therapy / GLP1 Combination Treatment / Obesity Drug Development / Fat Reduction Mechanism / Metabolic Therapy Innovation
Caliway’s CBL-514 shows potential in combination with GLP-1 receptor therapies for enhanced fat reduction, with preclinical data highlighting a synergistic approach to obesity treatment and advancing combination metabolic therapy strategies.
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
April 6, 2026 / Prader Willi Syndrome / Hyperphagia Treatment / Metabolic Disease Expansion / Rare Disease Obesity / Vykat XR
Neurocrine’s $2.9B acquisition of Soleno adds Vykat XR, targeting hyperphagia in Prader-Willi syndrome, marking strategic expansion into metabolic disorders and addressing severe obesity driven by rare genetic disease.
Imaging study measures pancreatic fat in children and teens
April 1, 2026 / Pancreatic Fat Imaging / Childhood Obesity Risk / Cardiometabolic Biomarkers / Insulin Resistance Children / Metabolic Syndrome Youth
Elevated pancreatic fat in obese children correlates with increased cardiometabolic risk, including higher BMI, visceral fat, blood pressure, and insulin resistance, supporting its role as an early biomarker for targeted intervention.
New obesity definition may delay treatment and complicate diagnosis
April 2, 2026 / Obesity Diagnosis Criteria / BMI Alternatives / Clinical Obesity Framework / Treatment Access Barriers / Health Equity Obesity
A revised obesity definition requiring evidence of organ dysfunction may delay diagnosis, complicate clinical workflows, and restrict treatment access, potentially worsening health inequities despite aiming to improve risk stratification beyond BMI.
Low-dose leukemia drug can clear senescent fat cells and cut inflammation
April 1, 2026 / Senescent Fat Cells / Homoharringtonine Therapy / Obesity Inflammation / Senolytic Treatment / Metabolic Disease Mechanisms
Low-dose homoharringtonine selectively clears senescent adipose cells, reducing inflammation and improving metabolic function in obesity models, highlighting a novel senolytic strategy to address insulin resistance and age-related metabolic disease.
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
April 6, 2026 / Prader Willi Syndrome / Hyperphagia Treatment / Metabolic Disease Expansion / Rare Genetic Obesity / Vykat XR
Neurocrine’s $2.9B acquisition of Soleno adds Vykat XR, targeting hyperphagia in Prader-Willi syndrome, strengthening its entry into metabolic disorders and addressing severe obesity driven by rare genetic disease.
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
April 7, 2025 / CB1 Receptor Antagonist / GLP1 Combination Therapy / Nimacimab Obesity / Peripheral CB1 Inhibition / Weight Loss Innovation
Nimacimab, a peripheral CB1 receptor antibody, shows additive weight-loss effects with GLP-1 therapies while minimizing neuropsychiatric risks, representing a novel combination strategy to enhance efficacy and durability in obesity treatment.
MASLD, MASH, and the Role of SGLT2 Inhibitors: Clinical Implications
April 6, 2026 / MASLD Treatment / MASH Therapy / SGLT2 Inhibitors / Liver Fat Reduction / Metabolic Liver Disease
SGLT2 inhibitors show potential in managing MASLD and MASH by reducing liver fat and improving metabolic parameters, with evolving roles in risk stratification, imaging-based assessment, and integrated care for patients with diabetes and liver disease.
Sagimet Biosciences to Present Phase 2b FASCINATE 2 Trial Data for Denifanstat at Keystone Symposium on Metabolic Drivers and Inflammatory Crosstalk
April 6, 2026 / Denifanstat MASH / Bile Acid Biomarkers / Metabolic Liver Disease / Phase 2b Trial / Liver Fibrosis Treatment
Denifanstat demonstrated significant bile acid reductions and histological improvements in MASH patients in Phase 2b trials, supporting its potential as a therapeutic option and highlighting bile acids as biomarkers for treatment response.
Wegovy approved to treat severe fatty liver disease
April 1, 2026 / Semaglutide MASH / Fatty Liver Treatment / GLP1 Liver Disease / Liver Fibrosis Therapy / Metabolic Liver Disease
Semaglutide (Wegovy) received provisional approval for treating non-cirrhotic MASH, demonstrating liver inflammation resolution and fibrosis improvement, though cost, access, and long-term outcomes remain key considerations in expanding metabolic liver disease management.
Prickly pear may pack a surprising punch against metabolic syndrome
April 6, 2025 / Prickly Pear Metabolism / Metabolic Syndrome Nutrition / Insulin Resistance Diet / Functional Foods Obesity / Antioxidant Phytochemicals
Prickly pear (Opuntia ficus-indica) shows potential in metabolic syndrome by improving insulin signaling, lipid metabolism, and inflammation via polyphenols, betalains, and fiber, though robust clinical evidence remains limited.